» Articles » PMID: 21114510

Serum IGF-1 Concentrations in a Sample of Patients with Traumatic Brain Injury As a Diagnostic Marker of Growth Hormone Secretory Response to Glucagon Stimulation Testing

Overview
Specialty Endocrinology
Date 2010 Dec 1
PMID 21114510
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The diagnosis of growth hormone deficiency (GHD) in adults is established through growth hormone (GH) stimulation testing, which is often complex, expensive, time-consuming and may be associated with adverse side effects. The decision to perform GH provocative testing is influenced by clinical findings, medical history and biochemical evidence. We report in this study our experience using the glucagon stimulation test (GST) in assessing GHD in adult patients with traumatic brain injury (TBI) as it relates to baseline serum insulin-like growth factor-1 (IGF-1) concentrations.

Design: A receiver operating characteristic (ROC) curve analysis was performed to determine the optimal IGF-1 cut-off for diagnosis of GHD at different potential diagnostic GST cut-off values (<3, <5, & <10 μg/l).

Patients: One hundred and thirty-eight patients (98 men and 40 women) with a documented history of moderate to severe TBI were assessed for GHD using serum IGF-1 concentrations and the GST.

Measurements: IGF-1 values were compared with peak GH values obtained following the GST.

Results: An IGF-1 cut-off value of 175 μg/l minimized the misclassification of GHD patients and GH-sufficient patients and provided a sensitivity of 83% and specificity of 40%, as well as a negative predictive power of 90% considering a criterion for peak GH response of <3 μg/l.

Conclusions: Our current findings are consistent with previous work assessing peak GH response using the insulin tolerance test (ITT) in a non-TBI sample, suggesting that diagnostic accuracy may be optimized if the GST is used when obtained serum IGF-1 concentrations are below 175 μg/l. While the decision to perform provocative testing to assess GHD in adult patients should be based on the clinician's clinical impression, the findings from this retrospective study can provide useful clinical information and serve as a guide.

Citing Articles

Acute and chronic hypopituitarism following traumatic brain injury: a systematic review and meta-analysis.

Aljboor G, Tulemat A, Al-Saedi A, Radoi M, Toader C, Papacocea T Neurosurg Rev. 2024; 47(1):841.

PMID: 39527353 PMC: 11554839. DOI: 10.1007/s10143-024-03088-3.


Early IGF-1 Gene Therapy Prevented Oxidative Stress and Cognitive Deficits Induced by Traumatic Brain Injury.

Montivero A, Ghersi M, Silvero C M, de la Villarmois E, Catalan-Figueroa J, Herrera M Front Pharmacol. 2021; 12:672392.

PMID: 34234671 PMC: 8255687. DOI: 10.3389/fphar.2021.672392.


Traumatic Brain Injury as Frequent Cause of Hypopituitarism and Growth Hormone Deficiency: Epidemiology, Diagnosis, and Treatment.

Gasco V, Cambria V, Bioletto F, Ghigo E, Grottoli S Front Endocrinol (Lausanne). 2021; 12:634415.

PMID: 33790864 PMC: 8005917. DOI: 10.3389/fendo.2021.634415.


Utility of serum IGF-1 for diagnosis of growth hormone deficiency following traumatic brain injury and sport-related concussion.

Lithgow K, Chin A, Debert C, Kline G BMC Endocr Disord. 2018; 18(1):20.

PMID: 29609574 PMC: 5879553. DOI: 10.1186/s12902-018-0247-1.


Chronic Hypopituitarism Associated with Increased Postconcussive Symptoms Is Prevalent after Blast-Induced Mild Traumatic Brain Injury.

Undurti A, Colasurdo E, Sikkema C, Schultz J, Peskind E, Pagulayan K Front Neurol. 2018; 9:72.

PMID: 29515515 PMC: 5825904. DOI: 10.3389/fneur.2018.00072.